Inhibikase Therapeutics (IKT) Liabilities and Shareholders Equity (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $173.3 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 83.85% year-over-year to $173.3 million in Q1 2026; TTM through Mar 2026 was $523.0 million, a 153.77% increase from a year earlier, with the FY2025 full-year figure at $181.2 million, up 83.78% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $173.3 million, down from $181.2 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for IKT reached as high as $181.2 million in Q4 2025 and fell as low as $4.4 million in Q3 2024.
• Historically, Liabilities and Shareholders Equity has averaged $55.8 million across 5 years, with a median of $28.6 million in 2022.
• Across the five-year window, Liabilities and Shareholders Equity sank 75.52% in 2024 and jumped 1718.52% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $24.9 million in 2022, then sank by 41.83% to $14.5 million in 2023, then jumped by 579.69% to $98.6 million in 2024, then soared by 83.78% to $181.2 million in 2025, then decreased by 4.34% to $173.3 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $173.3 million in Q1 2026, $181.2 million in Q4 2025, and $79.6 million in Q3 2025.